Pensando a proteção da propriedade intelectual em equilíbrio com o acesso ao conhecimento.
PROVIDENCE, R.I.
(Brown University) — Brazil’s nearly two-decade effort to treat people living with HIV and AIDS shows that developing countries can successfully combat the epidemic. Inexpensive generic medicines are a large part of the solution, say researchers from Brown University and the Harvard School of Public Health.
The National Institute on Industrial Property (INPI, acronym in Portuguese) published on June 30th the patent rejection for Tenofovir (Viread), produced by Gilead, which is used for HIV/AIDS treatment. According to data from the Ministry of Health’s STD and AIDS Department, Tenofovir accounts for 14,94% of the budget for the purchase of antiretrovirals (ARVs), being one of the most expensive medicines for treatment.
